News
Article
Author(s):
Len Rosenberg, head of clinical operations at Beat AML, reveals how changing the backbone treatment to a different regimen is beneficial to the patient, in terms of the safety with the same efficacy.
In an interview at the 2023 SCOPE conference with ACT Editor-in-Chief, Lisa Henderson, Len Rosenberg, head of clinical operations at Beat AML, explains the operational obstacles that come with clinical trials, including background treatment dosages.
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.